Effect and Safety of Kangfuyan Capsules (抗妇炎胶囊) for Relieving Chronic Pelvic Pain: A Multicenter, Randomized,Controlled, Double-Blind, Parallel-Group Clinical Trial

Zhao-hui LIU; Zhe JIN; Hong ZHAO; Yao LU; Hui ZHEN; Ting ZOU

doi:10.1007/s11655-021-3490-7

Your Location：

Home >

Browse articles >

Effect and Safety of Kangfuyan Capsules (抗妇炎胶囊) for Relieving Chronic Pelvic Pain: A Multicenter, Randomized,Controlled, Double-Blind, Parallel-Group Clinical Trial

Original Article | Updated：2021-11-29

- Effect and Safety of Kangfuyan Capsules (抗妇炎胶囊) for Relieving Chronic Pelvic Pain: A Multicenter, Randomized,Controlled, Double-Blind, Parallel-Group Clinical Trial
- Chinese Journal of Integrative Medicine Vol. 27, Issue 12, Pages: 883-890(2021)
- Affiliations：
  
  1.Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing (100026), China
  2.China Association of Traditional Chinese Medicine, Beijing(100101), China
  3.Department of Gynecology, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine,Beijing (100078), China
  4.Department of Gynecology, China-Japan Friendship Hospital, Beijing (100029), China
- Author bio：
  
  Prof. LIU Zhao-hui, E-mail: 17301255426@163.com;
  Prof. JIN Zhe, E-mail: jzhe0105@126.com
- Funds：
- DOI：10.1007/s11655-021-3490-7
  CLC：
- Published：15 November 2021，
  
  Published Online：25 August 2021，
  
  Accepted：24 April 2020
Scan for full text
Zhao-hui LIU, Zhe JIN, Hong ZHAO, et al. Effect and Safety of Kangfuyan Capsules (抗妇炎胶囊) for Relieving Chronic Pelvic Pain: A Multicenter, Randomized,Controlled, Double-Blind, Parallel-Group Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(12):883-890(2021)
DOI：

Zhao-hui LIU, Zhe JIN, Hong ZHAO, et al. Effect and Safety of Kangfuyan Capsules (抗妇炎胶囊) for Relieving Chronic Pelvic Pain: A Multicenter, Randomized,Controlled, Double-Blind, Parallel-Group Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(12):883-890(2021) DOI： 10.1007/s11655-021-3490-7.

摘要

目的

一项随机、双盲、平行对照、多中心临床试验

评价抗妇炎胶囊治疗盆腔炎性疾病-慢性盆腔痛的有效性、安全性.

方法

于2014年9月-2015年10月

在中国10家医院共纳入盆腔炎性疾病-慢性盆腔痛的患者240例

采用计算机生成随机数按照1:1比例随机分为2组

分别接受抗妇炎胶囊或宫炎平胶囊治疗

两组治疗方案均为4粒/次

3次/日

疗程12周

随访4周. 分别于基线、治疗1、2、3个月后评价视觉模拟量表(VAS) 评分、疾病疗效、各单项症状/体征愈显率和生活质量评分

同时观察不良事件.

结果

治疗3个月后

相对于对照组

抗妇炎组VAS评分下降更明显(

0.05); 而疾病疗效、下腹痛、子宫压痛、附件包块、附件压痛的愈显率以及健康生活质量(EQ-5D) 评分均高于对照组(

0.05). 不良事件主要包括肝酶升高、血红蛋白降低和血小板计数升高

所有不良事件程度为轻、中度.

结论

相较于宫炎平胶囊

抗妇炎胶囊治疗盆腔炎性疾病-慢性盆腔痛镇痛效果更显著

长期疗效更好

安全性良好. (注册登记号ChiCTR190022732)

Abstract

Objective:

To evaluate the effect and safety of Kangfuyan Capsules (抗妇炎胶囊) for treating pelvic inflammatory disease (PID) in patients with chronic pelvic pain (CPP) in a multicenter

randomized

controlled

double-blind

parallel-group clinical trial.

Methods:

Totally

240 PID patients with CPP were randomized into 2 groups using a computer generated random number at a 1:1 ratio from 10 hospitals in China between September 2014 and November 2015. Patients received either oral Kangfuyan Capsules or Gongyanping Capsules (宫炎平胶囊

control); the regimen for both groups comprised 4 capsules (3 times daily) for 12 weeks

with follow-up visit 4 weeks after treatment. The visual analogue scale (VAS) scores

clinical responses

remarkable cure rates for each symptom

and quality of life scores were assessed at baseline

and after 1

and 3 months. Adverse events were also recorded.

Results:

The VAS scores were significantly lower (

0.05)

whereas the clinical responses

remarkable cure rates for lower abdominal pain

uterine tenderness

adnexal mass

and adnexal tenderness

and health-related quality of life (EQ-5D) scores were higher in the Kangfuyan group than in the control group at 3 months (

0.05). Common treatment-related adverse events included high hepatic enzyme levels

reduced hemoglobin levels

and elevated platelet counts

although all the adverse events were either mild or moderate in severity.

Conclusion:

Compared with Gongyanping therapy

Kangfuyan therapy yielded markedly better analgesia effects for CPP caused by PID

with obvious long-term efficacy and good safety. (Registration No. ChiCTR190022732)

关键词

Keywords

pelvic inflammatory diseasechronic pelvic painKangfuyan Capsulerandomized controlleddouble-blind trialChinese medicine

references

McKee DL, Hu Z, Stahlman S. Incidence and sequelae of acute pelvic inflammatory disease among active component females, U.S. Armed Forces, 1996–2016. MSMR 2018;25:2-8.

Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross JDC. Antibiotic therapy for pelvic inflammatory disease.Cochrane Database Syst Rev 2017;4:CD010285. doi:10.1002/14651858.CD010285.pub2http://doi.org/10.1002/14651858.CD010285.pub2.

Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R.Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age—United States,2013–2014. MMWR Morb Mortal Wkly Rep 2017;66:80-83.

Owusu-Edusei K Jr, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013;40:197-201.

Kames LD, Rapkin AJ, Naliboff BD, Afifi S, Ferrer-Brechner T. Effectiveness of an interdisciplinary pain management program for the treatment of chronic pelvic pain. Pain 1990;41:41-46.

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. Atlanta, GA:Department of Health and Human Services, 2015. Available at http://www.cdc.gov/std/tg2015/evidence.htmhttp://www.cdc.gov/std/tg2015/evidence.htm

Zhang YZ, ed. Chinese medicine gynecology. 1st ed. Shanghai:Shanghai Science and Technology Press,2007:228-229.

Ness RB, Soper DE, Holley RL, Peipert J, Randall H,Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.Am J Obstet Gynecol 2002;186:929-937.

Sweet RL. Pelvic inflammatory disease: current concepts of diagnosis and management. Curr Infect Dis Rep 2012;14:194-203.

Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. New Engl J Med 2015;372:2039-2048.

Centers for Disease Control and Prevention. Pelvic inflammatory disease: STD treatment guidelines. Atlanta:Department of Health and Human Services, 2010. Available at http://www.cdc.gov/std/treatment/ 2010/pid.htmhttp://www.cdc.gov/std/treatment/ 2010/pid.htm.

Oh Y, Kwon YS, Jung BD. Anti-inflammatory effects of the natural compounds Cortex Phellodendri and Humulus japonicus on pelvic inflammatory disease in mice. Int J Med Sci 2017;14:729-734.

Zhao RH, Hao ZP, Zhang Y, Lian FM, Sun WW, Liu Y, et al. Controlling the recurrence of pelvic endometriosis after a conservative operation: comparison between Chinese herbal medicine and Western medicine. Chin J Integr Med 2013;19:820-825.

Vieira Pde B, Giordani RB, Macedo AJ, Tasca T. Natural and synthetic compound anti-Trichomonas vaginalis: an update review. Parasitol Res 2015;114:1249-1261.

He X, Fang J, Huang L, Wang J, Huang X. Sophora flavescens Ait: traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine.J Ethnopharmacol 2015;172:10-29.

Fan D, Zhou X, Zhao C, Chen H, Zhao Y, Gong X. Anti-inflammatory, antiviral and quantitative study of quercetin-3-O-β-D-glucuronide in Polygonum perfoliatum L. Fitoterapia 2011;82:805-810.

Bao Y, Yang L, Hua B, Hou W, Shi Z, Li W, et al. A systematic review and meta-analysis on the use of traditional Chinese medicine compound Kushen Injection for bone cancer pain. Support Care Cancer 2014;22:825-836.

Wang KW, Zhu JR, Shen LQ. A new lignan with anti-tumour activity from Polygonum perfoliatum L. Nat Prod Res 2013;27:568-573.

Zhang D, Liu ZH, Lin HX, Liao QP, Li SX, Sui L, et al.Effectiveness of Honghua Ruyi Wan combined with antibiotics for relief of pelvic inflammatory disease pain in women. Biomed Res 2017;28:4665-4670.

Crossman SH. The challenge of pelvic inflammatory disease. Am Fam Physician 2006;73:859-864.

Howard F. Chronic pelvic pain. Obstet Gynecol 2003;101:594-611.

Gao S, Zhang Q. Curative effect of Jin'gangteng Capsule combined with Kangfuxiaoyan suppository in the treatment of chronic pelvic inflammatory disease. Pak J Pharm Sci 2017;30:1943-1946.

Daniels J, Gray R, Hills RK, Latthe P, Buckley L, Gupta J,et al. Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. JAMA 2009;302:955-961.

Sri T, Southgate E, Kerry SR, Nightingale C, Oakeshott P.Health-related quality of life and Chlamydia trachomatis infection in sexually experienced female inner-city students:a community-based cross-sectional study. Int J STD AIDS 2017;28:367-371.

Cao C, Luo A, Wu P, Weng D, Zheng H, Wang S. Efficacy and safety of morinidazole in pelvic inflammatory disease:results of a multicenter, double-blind, randomized trial. Eur J Clin Microbiol Infect Dis 2017;36:1225-1230.

Mikamo H, Iwasaku K, Yamagishi Y, Matsumizu M,Nagashima M. Efficacy and safety of intravenous azithromycin followed by oral azithromycin for the treatment of acute pelvic inflammatory disease and perihepatitis in Japanese women. J Infect Chemother 2014;20:429-435.

Lee JH, Shin H, Kim YJ, Paek SH, Jin S, Ha UH. Pseudomonas aeruginosa-induced IL-1β production is inhibited by Sophora flavescens via the NF-κB/inflammasome pathways. J Microbiol 2014;52:1044-1049.

Chen Q, Duan X, Fan H, Xu M, Tang Q, Zhang L, et al. Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. Int Immunopharmacol 2017;53:149-157.

Choi YY, Kim MH, Han JM, Hong J, Lee TH, Kim SH, et al. The antiinflammatory potential of Cortex Phellodendron in vivo and in vitro: downregulation of NO and iNOS through suppression of NF-κB and MAPK activation. Int Immunopharmacol 2014;19:214-220.

Ying J, Zhou MJ, Chen HY, Chen L, Zhang W, Ji J, et al.Effect of essential oil on patients with chronic prostatitis/chronic pelvic pain syndrome: a pilot randomized controlled trial. Chin J Integr Med 2019;25:91-95.

Shen CC, Yang AC, Hung JH, Hu LY, Chiang YY, Tsai SJ.Risk of psychiatric disorders following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. J Psychosom Obstet Gynaecol 2016;37:6-11.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-Catenin Signaling Pathway

Related Author

No data

Related Institution

Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Science, Xiamen University

Fujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development

Department of General Surgery, First People's Hospital of Hangzhou Lin'an District

Institute of Chinese Medicine, The Chinese University of Hong Kong

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰